The Grifols webinar series on Therapeutic Drug Monitoring (TDM) in Inflammatory Bowel Disease (IBD) patients is designed to present a broad range of research to demonstrate how TDM can support personalized medicine and assist gastroenterologists in their clinical practice to enhance decision making and safety in IBD patients. Sessions explore the benefits of proactive TDM to personalized medicine, the role of Vedolizumab in the treatment of IBD patients, and the strategic and cost benefits of using biosimilars in TDM.


Session 2: Evidences of the Utility of Vedolizumab Drug Level Monitoring in IBD Patients